Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558844 | 0.86 | KIF18A (0.36) | KIF18ASCN10AHIF1A | |
| SCHEMBL3543810 | 0.81 | MAPT (0.42) | — | |
| SCHEMBL10278269 | 0.79 | GRIN2D (0.42) | SCN10A | |
| SCHEMBL3435696 | 0.77 | OPRK1 (0.42) | PTPN11SCN10AADORA2ARPS6KB1 | |
| SCHEMBL10276904 | 0.75 | L3MBTL1 (0.41) | KIF18ASCN10A | |
| SCHEMBL3436543 | 0.73 | KIF18A (0.35) | KIF18APTPN11SCN10A | |
| SCHEMBL3569131 | 0.72 | ADRA2C (0.47) | — | |
| SCHEMBL3954751 | 0.72 | GRIN2D (0.40) | SCN10A | |
| SCHEMBL3436541 | 0.71 | OPRM1 (0.38) | KIF18ASCN10A | |
| SCHEMBL3577093 | 0.71 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | KIF18A 1520/4885PTPN11 420/4885SCN10A 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.